NCT03018730View on ClinicalTrials.gov

Safety and Efficacy of PRX-102 in Patients With Fabry Disease Currently Treated With REPLAGAL® (Agalsidase Alfa)

PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 17, 2017

Primary Completion Date

December 17, 2019

Study Completion Date

January 9, 2020

Conditions

Fabry Disease

Interventions

BIOLOGICAL

PRX-102 (pegunigalsidase alfa)

PRX-102 1 mg/kg every 2 weeks

Trial Locations (9)

3050

Royal Melbourne Hospital, Parkville

B3H 1V8

Capital Health, Halifax

Unknown

Vseobecna fakultni nemocnice v Praze, Prague

Academisch Medisch Centrum, Amsterdam

Helse Bergen HF Haukeland Universitetssykehus, Bergen

SI-2380

General Hospital Slovenj Gradec, Slovenj Gradec

B15 2TH

Queen Elizabeth Hospital, Department of Neurology,, Edgbaston

NW3 2QG

The Royal Free Hospital, London

M6 8HD

Salford Royal NHS Foundation Trust, Salford

All Listed Sponsors

collaborator

Chiesi Farmaceutici S.p.A.

INDUSTRY

lead

Protalix

INDUSTRY

NCT03018730 - Safety and Efficacy of PRX-102 in Patients With Fabry Disease Currently Treated With REPLAGAL® (Agalsidase Alfa) | Biotech Hunter | Biotech Hunter